Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1

Pediatric Infectious Disease Journal

Volumn 31, Issue 5, 2012, Pages 527-529

  Maltezou, Helena C ^a   Drakoulis, Nikolaos ^b   Siahanidou, Tania ^b   Karalis, Vangelis ^b   Zervaki, Eirini ^b   Dotsikas, Yannis ^b,c   Loukas, Yannis L ^b   Theodoridou, Maria ^b  

^a Hellenic Centre for Disease Control and Prevention   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Neoscreen Ltd   (Greece)

Author keywords

Influenza H1N1; Neonates; Oseltamivir; Pharmacokinetics; prophylaxis

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; LORATADINE; OSELTAMIVIR;

ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLUENZA A (H1N1); LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; NEWBORN; NEWBORN INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VOMITING;

ANTIVIRAL AGENTS; CHEMOPREVENTION; FEMALE; HUMANS; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; OSELTAMIVIR;

EID: 84860238462     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182472f28     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Available at: http://www.cdc.gov/h1n1flu/recommendations.htm#table1. Accessed March 26, 2011.
2. European Medicines Agency. Assessment Report for Tamiflu, International Nonproprietary Name: Oseltamivir. London: European Medicines Agency; 2009. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Assessment-Report-Variation/human/000402/WC500033109.pdf. Accessed March 26, 2011.
3. Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis. 2010;202:563-566.
4. Lindeǵdh N, Hanpithakpong W, Wattanagoon Y, et al. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;859:74-83.
5. Medicines and Healthcare Products Regulatory Agency. Summary of product characteristics, Tamiflu 30/45 mg hard capsule. Available at: www.mhra. gov.uk/home/groups/comms-ic/documents/websiteresources/con046639. pdf. Accessed October 8, 2011.
6. PubChem (The PubChem project). Available at: http://pubchem.ncbi.nlm.nih. gov. Accessed October 8, 2011.
7. Ette EI, Williams P, Fadiran E, et al. The process of knowledge discovery from large pharmacokinetic data sets. J Clin Pharmacol. 2001;41: 25-34.
8. Routledge P. Pharmacokinetics in children. J Antimicrob Chemother. 1994;34(suppl A):19-24.
9. MONOLIX Development Team, INRIA. The Monolix Software. Available at: http://www.monolix.org/sdoms/software/. Accessed October 8, 2011.
10. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Statist Data Anal. 2005;49:1020-1038.
11. Oo C, Hill G, Dorr A, et al. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003;59:411-415.
12. Meibohm B, Laer S, Panetta J, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7:E475-E487.